Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests the safety and effectiveness of the medications NA-931 and tirzepatide in adults who are overweight or obese over a 48-week period.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 224 people Planned (estimated).

Who can join Ages 19–80 · all sexes

Timeline Started 2026-08 · est. completion 2027-12

Where 17 sites · Australia, New Zealand, United States

What this study is testing ClinicalTrials.gov NCT06732245 ↗

Description as written by the study sponsor.

A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

Treatments tested

NA-931 also known as Tirzepatide placebo Drug

NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (Zepbound) placebo
Tirzepatide also known as NA-931 Placebo Drug

Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound NA-931 Placebo (oral, daily)
Tirzepatide also known as NA-931 Placebo Drug

Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound NA-931 Placebo (oral, daily)
NA-931 Drug

NA-931, an oral, daily • A quadruple receptor agonist
NA-931 also known as Tirzepatide Drug

NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
NA-931 also known as Tirzepatide Drug

NA-931 (oral daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
NA-931 150 mg + no Tirzepatide Drug

NA-931 150 mg + no Tirzepatide
NA-931 also known as Tirzepatide Drug

NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
NA-931 also known as Tirzepatide Drug

NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound

Main thing measured	Change from baseline in body weight at 48 weeks
Sponsor	Biomed Industries, Inc.
Conditions studied	Obesity and Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06732245 ↗